Why Lower ApoB Longer Reduces Heart Disease Risk? | T. Dayspring & D. Soffer | EP#430
ApoB is established as a driver of atherosclerosis based on multiple types of evidence including clinical trials, observational studies, and genetic data. Lower ApoB levels for longer periods reduce heart disease risk, with clinical evidence showing continued cardiovascular benefit even when LDL-C is reduced from 70 to 15 mg/dL.
Summary
The speakers discuss why lower ApoB for extended periods reduces heart disease risk. They establish that ApoB is a causal driver of atherosclerosis, supported by multiple lines of evidence: clinical trials, observational studies, survey data, randomized controlled trials, and genetic data from Mendelian randomization studies. Major medical societies, including the European Atherosclerosis Society, have recognized both LDL cholesterol and ApoB as causes of atherosclerotic disease based on this comprehensive evidence base. The speakers reference a landmark study led by Brian Ference that analyzed numerous clinical trials, represented as individual data points on a graph showing baseline LDL-C and post-treatment levels. The key finding from this meta-analysis is that all treatment curves show downward trends in cardiovascular events as LDL-C decreases. Notably, even when LDL-C levels were lowered to very low levels (from 70 to 15 mg/dL), there continued to be further reductions in cardiovascular events, suggesting a dose-response relationship without apparent lower threshold. This combination of diverse evidence types provides strong justification for establishing a cause-and-effect relationship between ApoB/LDL-C levels and atherosclerotic disease.
Key Insights
- Multiple independent lines of evidence—clinical trials, observational studies, randomized controlled data, and Mendelian randomization genetic data—all converge to establish ApoB as a causal driver of atherosclerosis
- The European Atherosclerosis Society and other leading medical societies have formally recognized LDL cholesterol and ApoB as causes of atherosclerotic disease based on comprehensive analysis of etiological evidence
- A meta-analysis by Brian Ference examining multiple clinical trials shows that all treatment curves demonstrate reduced cardiovascular events as LDL-C levels decrease from baseline
- Cardiovascular benefit continues even at very low LDL-C levels, with further event reductions observed when LDL-C is lowered from 70 to 15 mg/dL, suggesting no apparent lower threshold for benefit
- The combination of clinical trial data, observational studies, survey data, and randomized controlled evidence provides sufficient justification for establishing a definitive cause-and-effect relationship between ApoB/LDL-C and atherosclerotic disease
Topics
Transcript
[0:00] What evidence is there that gives you reason to say so? The lower the better, and for the longer term. ApoB is a driver of atherosclerosis . We have a wealth of clinical trials providing evidence pointing to etiological factors in atherosclerosis, as well as observational studies, survey data, randomized controlled data, and now genetic data from Mendelian randomization. And if you put all of this together , as the leading medical societies did—the first was the European [0:31] Atherosclerosis Society—they recognized LDL cholesterol and ApoB as the cause of this disease based on these tests. We have great graphics. Brian Ference was the lead author of this study, where each dot represents one of these clinical trials: baseline…
Full transcript available for MurmurCast members
Sign Up to AccessMore from The Proof with Simon Hill
MASH vs. MASLD: Which Medications Are Actually FDA Approved for Weight Loss? | Dr Mauricio Gonzalez
Dr. Mauricio Gonzalez clarifies that the United States has two FDA-approved medications specifically for MASH (metabolic dysfunction-associated steatohepatitis): resmetirom and semaglutide (Wegovy). However, for pure MASLD (metabolic dysfunction-associated fatty liver disease) without inflammation, there are currently no FDA-approved medications.
How Effective Are Weight Loss Drugs? The Risk and Limitations You Should Know About | EP#422
GLP-1 weight loss drugs are significantly more effective than diet alone, with 90-95% of clinical trial participants losing weight, but real-world non-response rates reach 20%. However, discontinuation rates are high (75% within 18 months), and without proper nutrition and exercise support, users risk losing up to 40% muscle mass while regaining primarily fat, creating sarcopenic obesity.
What Is the MIND Diet? (You Don't Have to Eat Perfectly) | Dr Terry Simpson
The MIND diet combines Mediterranean and DASH diets, focusing on increased fruits, vegetables, legumes, whole grains, and healthy fats while reducing red meat. Dr. Simpson emphasizes that perfection isn't required—studies show people scoring around 12.5 out of 15 points experienced the most benefits.
How Does HeartFlow's AI Analyze Your Heart Scan? | Dr Campbell Rogers | EP#426
Dr. Campbell Rogers explains HeartFlow's AI analysis process for heart scans, emphasizing that the company assesses image quality first, rejecting approximately 2-3% of scans that are too fuzzy. He highlights that scanner type, procedure techniques, and medications used at each site significantly impact image quality and the ability to track disease progression over time.
Muscle Loss Fix: Why Movement Beats More Protein | Simon Hill
Protein is often overemphasized in discussions about muscle loss, but the real driver of sarcopenia in America is sedentary lifestyle and lack of resistance training stimulus. Most people consume sufficient protein; the limiting factor is movement and strength training, not dietary protein intake.